Company intelligence / Profile preview

Genbioma Aplicaciones

Navarra, Navarra, Spain

Ownership: Private
Development stage: Other

Overview

Genbioma’s postbiotic pA1cHI has demonstrated significant reduction in HbA1c, body weight, BMI, and fat mass in a randomized, placebo-controlled pilot trial in obese individuals, with larger clinical trials underway for type 2 diabetes. Preclinical studies and early clinical data support efficacy in modulation of metabolic markers and prevention of diabetes progression[5].

Therapeutic areas: CardiovascularEndocrinology
Modalities: ProbioticPostbioticMicrobial therapyLive biotherapeutic product therapyNutritional ingredient
Industry: Biotech

Drug pipeline

2 assets

Pediococcus acidilactici CECT9879

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

EIT Food AcceleratorHospital Universitario VinalopóSandwalk Bioventures SL

Beyond the preview

Go deeper on Genbioma Aplicaciones.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genbioma Aplicaciones.

Explore the full profile